BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2520 related articles for article (PubMed ID: 17587883)

  • 1. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic criteria and classification of mastocytosis: a consensus proposal.
    Valent P; Horny HP; Escribano L; Longley BJ; Li CY; Schwartz LB; Marone G; Nuñez R; Akin C; Sotlar K; Sperr WR; Wolff K; Brunning RD; Parwaresch RM; Austen KF; Lennert K; Metcalfe DD; Vardiman JW; Bennett JM
    Leuk Res; 2001 Jul; 25(7):603-25. PubMed ID: 11377686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms.
    Valent P; Sperr WR; Schwartz LB; Horny HP
    J Allergy Clin Immunol; 2004 Jul; 114(1):3-11; quiz 12. PubMed ID: 15241337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mastocytosis, classification, biological diagnosis and therapy].
    Arock M
    Ann Biol Clin (Paris); 2004; 62(6):657-69. PubMed ID: 15563424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2010; 77(4):169-80. PubMed ID: 20616612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mastocytosis.
    Metcalfe DD
    Novartis Found Symp; 2005; 271():232-42; discussion 242-9. PubMed ID: 16605139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
    Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
    Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary role of multiparametric flow cytometry in the diagnostic work-up of indolent clonal mast cell disorders.
    Perbellini O; Zamò A; Colarossi S; Zampieri F; Zoppi F; Bonadonna P; Schena D; Artuso A; Martinelli G; Chilosi M; Pizzolo G; Zanotti R
    Cytometry B Clin Cytom; 2011 Nov; 80(6):362-8. PubMed ID: 21656905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
    Pardanani A
    Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia.
    Krokowski M; Sotlar K; Krauth MT; Födinger M; Valent P; Horny HP
    Am J Clin Pathol; 2005 Oct; 124(4):560-8. PubMed ID: 16146815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
    Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
    Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis.
    Hahn HP; Hornick JL
    Am J Surg Pathol; 2007 Nov; 31(11):1669-76. PubMed ID: 18059223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
    Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
    J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis, clinical features, and treatment advances in mastocytosis.
    Pardanani A; Akin C; Valent P
    Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mastocytosis - an update.
    Amon U; Hartmann K; Horny HP; Nowak A
    J Dtsch Dermatol Ges; 2010 Sep; 8(9):695-711; quiz 712. PubMed ID: 20678151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on Mastocytosis (Part 2): Categories, Prognosis, and Treatment.
    Azaña JM; Torrelo A; Matito A
    Actas Dermosifiliogr; 2016; 107(1):15-22. PubMed ID: 26525106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biology, classification and treatment of human mastocytosis.
    Valent P
    Wien Klin Wochenschr; 1996; 108(13):385-97. PubMed ID: 8766423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 126.